GlobeNewswire
Contact Us
Register
Sign In
English
Français
About this file
Figure 1
WOMAC Question A1 Pain Score Averages (Treated versus Saline Control) – Cohort 1 (5 μg).
Sorrento Therapeutics, Inc.
Format
JPEG
Source
Sorrento Therapeutics, Inc.
Downloads
Original
Large
Medium
Small
ASSOCIATED PRESS RELEASE
Sorrento Therapeutics Announces Interim Results In Osteoarthritis Knee Pain Phase 1b Trial of Resiniferatoxin With Positive Therapeutic Signal and Absence of Dose Limiting Toxicities; Pivotal Trials Targeted to Start Later 2019
Published
January 22, 2019 07:00 ET